Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Evopoint Options-Out Rights for Pre-clinical Solid Tumor ADC to AmMax

publication date: Jan 11, 2023

Suzhou Evopoint Biosciences optioned out global rights (ex-China) for a pre-clinical ADC asset that targets solid tumor cancers to AmMax, a Redwood City, CA company. The option specifies the licensing terms. The two companies intend to work together to complete an upcoming IND filing and design dose-escalating clinical studies. Evopoint has built a novel pipeline of six clinical and 15 pre-clinical candidates in oncology, anti-infectives and metabolic diseases. AmMax, which claims expertise in translational and clinical development, has built an oncology portfolio via licensing and partnerships. Evopoint is the new name for Sinovent. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital